KMT2A: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
 
Line 1: Line 1:
{{Short description|Overview of the KMT2A gene and its significance in human biology}}
= KMT2A =


==KMT2A Gene==
[[File:9aaTADs_in_the_E_protein_family.jpg|thumb|right|300px|Structure of 9aaTADs in the E protein family, relevant to KMT2A function.]]
The '''KMT2A''' gene, also known as '''MLL''' (Mixed-Lineage Leukemia), is a crucial gene located on chromosome 11q23.3. It encodes a protein that functions as a histone methyltransferase, which is essential for the regulation of gene expression through chromatin modification. The KMT2A protein plays a significant role in the regulation of [[gene expression]], [[cell cycle]], and [[developmental processes]].


[[File:Histone methylation.png|thumb|right|300px|Histone methylation is a key process regulated by KMT2A.]]
'''KMT2A''', also known as '''lysine methyltransferase 2A''', is a [[gene]] that encodes a protein involved in the regulation of [[gene expression]] through [[histone modification]]. This gene is located on [[chromosome 11]] in humans and is a member of the [[SET domain]] family of proteins, which are known for their role in [[epigenetic]] regulation.


==Function==
== Function ==
The KMT2A protein is part of a large multiprotein complex that specifically methylates histone H3 at lysine 4 (H3K4). This methylation is a marker of active chromatin and is associated with transcriptional activation. The KMT2A complex is involved in the regulation of [[homeobox]] (HOX) genes, which are critical for embryonic development and hematopoiesis.
KMT2A is a [[histone methyltransferase]] that specifically methylates [[histone H3]] at lysine 4 (H3K4). This modification is associated with [[transcriptional activation]] and is crucial for the regulation of [[gene expression]] during [[development]] and [[cell differentiation]]. The protein encoded by KMT2A contains several important domains, including a [[SET domain]], which is responsible for its methyltransferase activity, and [[PHD finger]] domains, which are involved in recognizing specific histone modifications.


==Clinical Significance==
== Clinical significance ==
Mutations and translocations involving the KMT2A gene are implicated in various forms of [[leukemia]], particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). These genetic alterations often result in the formation of fusion proteins that disrupt normal gene regulation, leading to uncontrolled cell proliferation.
Mutations and rearrangements involving the KMT2A gene are implicated in various forms of [[leukemia]], particularly [[acute lymphoblastic leukemia]] (ALL) and [[acute myeloid leukemia]] (AML). These rearrangements often result in the formation of [[fusion proteins]] that disrupt normal gene regulation and contribute to the development of cancer.


===Leukemia===
== Structure ==
Translocations involving KMT2A are found in approximately 5-10% of acute leukemias. The most common translocation is t(4;11)(q21;q23), which results in the fusion of KMT2A with the AF4 gene. This fusion protein acts as an aberrant transcription factor, driving the expression of genes that promote leukemogenesis.
[[File:Piskacek_Figures_v9b.jpg|thumb|left|300px|Diagram illustrating the structural domains of KMT2A.]]
The KMT2A protein is a large, multi-domain protein that includes several [[zinc finger]] motifs, [[AT hooks]], and a [[SET domain]]. The presence of these domains allows KMT2A to interact with [[DNA]] and other [[chromatin]] components, facilitating its role in modifying chromatin structure and regulating gene expression.


[[File:Leukemia cells.png|thumb|left|300px|Leukemia cells often exhibit chromosomal translocations involving KMT2A.]]
== Interactions ==
KMT2A interacts with a variety of other proteins to form a [[protein complex]] that is essential for its function in histone methylation. These interactions include binding with [[WDR5]], [[ASH2L]], and [[RBBP5]], which are components of the [[COMPASS complex]]. This complex is responsible for the trimethylation of H3K4, a key marker of active chromatin.


==Research and Therapeutic Approaches==
== Related pages ==
Research into the KMT2A gene and its associated pathways is ongoing, with the aim of developing targeted therapies for leukemias involving KMT2A translocations. Strategies include the use of small molecule inhibitors that target the KMT2A fusion proteins or their downstream signaling pathways.
 
==Related Pages==
* [[Histone methylation]]
* [[Histone methylation]]
* [[Chromatin remodeling]]
* [[Epigenetics]]
* [[Acute lymphoblastic leukemia]]
* [[Chromatin]]
* [[Acute myeloid leukemia]]
* [[Leukemia]]
* [[Gene expression regulation]]
* [[Gene expression]]


[[Category:Genes on human chromosome 11]]
[[Category:Genes on human chromosome 11]]
[[Category:Epigenetics]]
[[Category:Histone-modifying enzymes]]
[[Category:Histone-modifying enzymes]]
[[Category:Leukemia]]

Latest revision as of 14:11, 21 February 2025

KMT2A[edit]

Structure of 9aaTADs in the E protein family, relevant to KMT2A function.

KMT2A, also known as lysine methyltransferase 2A, is a gene that encodes a protein involved in the regulation of gene expression through histone modification. This gene is located on chromosome 11 in humans and is a member of the SET domain family of proteins, which are known for their role in epigenetic regulation.

Function[edit]

KMT2A is a histone methyltransferase that specifically methylates histone H3 at lysine 4 (H3K4). This modification is associated with transcriptional activation and is crucial for the regulation of gene expression during development and cell differentiation. The protein encoded by KMT2A contains several important domains, including a SET domain, which is responsible for its methyltransferase activity, and PHD finger domains, which are involved in recognizing specific histone modifications.

Clinical significance[edit]

Mutations and rearrangements involving the KMT2A gene are implicated in various forms of leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). These rearrangements often result in the formation of fusion proteins that disrupt normal gene regulation and contribute to the development of cancer.

Structure[edit]

Diagram illustrating the structural domains of KMT2A.

The KMT2A protein is a large, multi-domain protein that includes several zinc finger motifs, AT hooks, and a SET domain. The presence of these domains allows KMT2A to interact with DNA and other chromatin components, facilitating its role in modifying chromatin structure and regulating gene expression.

Interactions[edit]

KMT2A interacts with a variety of other proteins to form a protein complex that is essential for its function in histone methylation. These interactions include binding with WDR5, ASH2L, and RBBP5, which are components of the COMPASS complex. This complex is responsible for the trimethylation of H3K4, a key marker of active chromatin.

Related pages[edit]